Free Trial

FY2025 EPS Estimates for MRK Decreased by Cantor Fitzgerald

Merck & Co., Inc. logo with Medical background

Merck & Co., Inc. (NYSE:MRK - Free Report) - Cantor Fitzgerald cut their FY2025 earnings per share estimates for shares of Merck & Co., Inc. in a research note issued to investors on Wednesday, July 9th. Cantor Fitzgerald analyst C. Gould now expects that the company will post earnings of $8.66 per share for the year, down from their previous forecast of $8.88. Cantor Fitzgerald currently has a "Cautious" rating on the stock. The consensus estimate for Merck & Co., Inc.'s current full-year earnings is $9.01 per share. Cantor Fitzgerald also issued estimates for Merck & Co., Inc.'s FY2026 earnings at $9.55 EPS.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $2.22 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.06. The firm had revenue of $15.53 billion for the quarter, compared to analyst estimates of $15.59 billion. Merck & Co., Inc. had a return on equity of 43.23% and a net margin of 27.27%. The business's quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.07 EPS.

Other research analysts have also issued reports about the company. Morgan Stanley decreased their target price on Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating on the stock in a report on Thursday. Citigroup reissued a "neutral" rating and set a $84.00 target price (down from $115.00) on shares of Merck & Co., Inc. in a report on Wednesday, May 14th. Wall Street Zen downgraded Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a research note on Friday, April 25th. Finally, Guggenheim restated a "buy" rating and issued a $115.00 price target on shares of Merck & Co., Inc. in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $108.69.

Read Our Latest Report on MRK

Merck & Co., Inc. Stock Performance

Shares of MRK stock traded down $0.76 during trading on Thursday, reaching $83.26. 5,016,145 shares of the company's stock were exchanged, compared to its average volume of 13,376,114. The company has a quick ratio of 1.16, a current ratio of 1.41 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $209.06 billion, a PE ratio of 12.12, a PEG ratio of 0.87 and a beta of 0.39. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $129.93. The firm's fifty day moving average price is $79.07 and its 200-day moving average price is $86.60.

Hedge Funds Weigh In On Merck & Co., Inc.

Institutional investors and hedge funds have recently bought and sold shares of the company. Barnes Dennig Private Wealth Management LLC acquired a new position in Merck & Co., Inc. in the 1st quarter worth about $27,000. WealthTrak Capital Management LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $35,000. Spurstone Advisory Services LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $37,000. CBIZ Investment Advisory Services LLC increased its stake in shares of Merck & Co., Inc. by 141.7% in the first quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company's stock valued at $34,000 after buying an additional 221 shares during the period. Finally, Hurley Capital LLC acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at about $40,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Insider Buying and Selling at Merck & Co., Inc.

In related news, SVP Dalton E. Smart III sold 4,262 shares of the company's stock in a transaction on Friday, April 25th. The stock was sold at an average price of $82.76, for a total transaction of $352,723.12. Following the completion of the sale, the senior vice president directly owned 7,778 shares in the company, valued at $643,707.28. This represents a 35.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, July 8th. Investors of record on Monday, June 16th were given a dividend of $0.81 per share. The ex-dividend date of this dividend was Monday, June 16th. This represents a $3.24 annualized dividend and a dividend yield of 3.89%. Merck & Co., Inc.'s dividend payout ratio is currently 47.16%.

Merck & Co., Inc. Company Profile

(Get Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Stories

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines